{"id":10181,"date":"2026-06-11T09:50:50","date_gmt":"2026-06-11T14:50:50","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10181"},"modified":"2026-06-11T10:14:32","modified_gmt":"2026-06-11T15:14:32","slug":"nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/","title":{"rendered":"Nanoscope Therapeutics anuncia la publicaci\u00f3n del estudio precl\u00ednico sobre la terapia g\u00e9nica MCO-010, que demuestra efectos restauradores de la visi\u00f3n y modificadores de la enfermedad en pacientes con enfermedad de Stargardt."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10181\" class=\"elementor elementor-10181\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><h3><em>Una \u00fanica inyecci\u00f3n intrav\u00edtrea de MCO-010 produjo una mejora sostenida en el comportamiento guiado visualmente en un modelo precl\u00ednico de la enfermedad de Stargardt.<\/em><\/h3><\/li><li><h3><em>El tratamiento con MCO-010 mostr\u00f3 aumentos significativos en la respuesta fisiol\u00f3gica de la retina, sin cambios notables en el grosor de la retina, lo que sugiere un posible efecto modificador de la enfermedad.<\/em><\/h3><\/li><li><h3><em>Los hallazgos refuerzan el mecanismo independiente de mutaciones de MCO-010 y su ventaja de administraci\u00f3n intrav\u00edtrea en una enfermedad sin tratamiento aprobado.<\/em><\/h3><\/li><\/ul><p><strong>DALLAS, 11 de junio de 2026<\/strong> \u2014 Nanoscope Therapeutics Inc., una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y deterioro de la visi\u00f3n debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy la publicaci\u00f3n en la revista,\u00a0<em>Bioingenier\u00eda,\u00a0<\/em>Los resultados demuestran que una \u00fanica inyecci\u00f3n intrav\u00edtrea de MCO-010, una terapia optogen\u00e9tica en fase de investigaci\u00f3n, mejor\u00f3 significativamente la funci\u00f3n visual y preserv\u00f3 la arquitectura de la retina en un modelo de rat\u00f3n de la enfermedad de Stargardt.<\/p><p>La enfermedad de Stargardt es la degeneraci\u00f3n macular juvenil hereditaria m\u00e1s com\u00fan, que afecta aproximadamente a 1 de cada 8000 a 10 000 personas, sin que exista hasta la fecha ning\u00fan tratamiento aprobado por la FDA. Los enfoques convencionales de reemplazo gen\u00e9tico requieren fotorreceptores viables y se ven limitados por el gran tama\u00f1o del gen ABCA4, que excede la capacidad de empaquetamiento de los vectores AAV est\u00e1ndar. MCO-010 evita por completo esta limitaci\u00f3n al dirigirse a las c\u00e9lulas bipolares ON supervivientes situadas aguas abajo de los fotorreceptores degenerados.<\/p><p>En el estudio, se trat\u00f3 la opsina multicaracter\u00edstica (MCO-010). <em>Abca4<\/em>Los ratones \u207b\/\u207b navegaron por un laberinto acu\u00e1tico radial mucho m\u00e1s r\u00e1pido que los ratones control tratados con el veh\u00edculo AAV2. Adem\u00e1s, se observaron aumentos en la amplitud de la onda B, lo que indica mejoras en la funci\u00f3n retiniana, sin una disminuci\u00f3n adicional del grosor de la retina, en comparaci\u00f3n con un adelgazamiento retiniano medible en los ratones control. Este efecto es consistente con un posible mecanismo modificador de la enfermedad. La inmunohistoqu\u00edmica confirm\u00f3 una expresi\u00f3n robusta y dirigida de MCO-010 en las c\u00e9lulas bipolares ON de la retina interna al final del estudio.<\/p><p>\u201cEstos resultados refuerzan el potencial de MCO-010 no solo para restaurar la visi\u00f3n, sino tambi\u00e9n para modificar el curso de la degeneraci\u00f3n retiniana, un resultado que no se ha demostrado con ninguna terapia aprobada\u2019, afirm\u00f3 Samarendra Mohanty, PhD, fundador y presidente de Nanoscope Therapeutics. \u201dLa durabilidad de la respuesta, junto con la preservaci\u00f3n estructural de la retina, refuerza nuestra confianza en MCO-010 como una terapia de plataforma aplicable a un amplio espectro de enfermedades degenerativas de la retina externa\u201c.\u201d<\/p><p>Los resultados del estudio est\u00e1n disponibles en l\u00ednea en <em>Bioingenier\u00eda<\/em>\u00a0<a href=\"https:\/\/www.mdpi.com\/2306-5354\/13\/6\/660\">aqu\u00ed<\/a>.<\/p><p><strong>Avanzando hacia la comercializaci\u00f3n<\/strong><strong><br \/><\/strong>Nanoscope contin\u00faa impulsando los avances cl\u00ednicos, regulatorios y de producci\u00f3n a gran escala de MOGENRY (MCO-010) para la retinosis pigmentaria, incluyendo el progreso de su solicitud de licencia para productos biol\u00f3gicos en EE. UU. La compa\u00f1\u00eda tambi\u00e9n ha establecido una creciente base regulatoria global para MOGENRY, con las designaciones de medicamento hu\u00e9rfano, v\u00eda r\u00e1pida y RMAT en EE. UU., y las designaciones de Sakigake y medicamento hu\u00e9rfano en Jap\u00f3n, cinco designaciones de medicamento hu\u00e9rfano de la EMA para distrofias retinianas hereditarias y, m\u00e1s recientemente, una designaci\u00f3n de medicamento hu\u00e9rfano para distrofias retinianas hereditarias en Arabia Saudita. Estos hitos reflejan la creciente trayectoria regulatoria internacional de la compa\u00f1\u00eda a medida que avanza en la planificaci\u00f3n de su comercializaci\u00f3n en mercados globales clave.<\/p><p><strong>Acerca de la plataforma MCO<\/strong><strong><br \/><\/strong>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><strong>Acerca de Nanoscope Therapeutics<\/strong><\/p><p>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\">NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en SD (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\">Ensayo de registro de fase 3<\/a>\u00a0En 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en GA comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p><p>Contacto: Nanoscope Therapeutics, Inc.<br \/>+1 (817) 857-1186<br \/><a href=\"mailto:PR@nanostherapeutics.com\">PR@nanostherapeutics.com<\/a><\/p><p>\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Single intravitreal injection of MCO-010 produced sustained improvement in visually guided behavior in preclinical model of Stargardt disease MCO-010-treatment showed significant increases in retinal physiologic response, with no notable change in retinal thickness, suggesting a potential disease-modifying effect Findings reinforce MCO-010&#8217;s mutation-agnostic mechanism and intravitreal delivery advantage in a disease with no approved treatment DALLAS, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10182,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10181","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-11T14:50:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-11T15:14:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study\",\"datePublished\":\"2026-06-11T14:50:50+00:00\",\"dateModified\":\"2026-06-11T15:14:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/\"},\"wordCount\":700,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_MDPI-Bioengineering-PUblication_REV2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/\",\"name\":\"Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_MDPI-Bioengineering-PUblication_REV2.jpg\",\"datePublished\":\"2026-06-11T14:50:50+00:00\",\"dateModified\":\"2026-06-11T15:14:32+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_MDPI-Bioengineering-PUblication_REV2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_MDPI-Bioengineering-PUblication_REV2.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/11\\\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia la publicaci\u00f3n del estudio precl\u00ednico sobre la terapia g\u00e9nica MCO-010, que demuestra efectos restauradores de la visi\u00f3n y modificadores de la enfermedad en la enfermedad de Stargardt. - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-06-11T14:50:50+00:00","article_modified_time":"2026-06-11T15:14:32+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study","datePublished":"2026-06-11T14:50:50+00:00","dateModified":"2026-06-11T15:14:32+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/"},"wordCount":700,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_MDPI-Bioengineering-PUblication_REV2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/","url":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/","name":"Nanoscope Therapeutics anuncia la publicaci\u00f3n del estudio precl\u00ednico sobre la terapia g\u00e9nica MCO-010, que demuestra efectos restauradores de la visi\u00f3n y modificadores de la enfermedad en la enfermedad de Stargardt. - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_MDPI-Bioengineering-PUblication_REV2.jpg","datePublished":"2026-06-11T14:50:50+00:00","dateModified":"2026-06-11T15:14:32+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_MDPI-Bioengineering-PUblication_REV2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_MDPI-Bioengineering-PUblication_REV2.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/11\/nanoscope-therapeutics-announces-the-publication-of-mco-010-gene-therapy-demonstrating-vision-restoring-and-disease-modifying-effects\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10181"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10181\/revisions"}],"predecessor-version":[{"id":10189,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10181\/revisions\/10189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10182"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}